SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Holdings

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Richard Strutz who wrote (138)4/13/1999 12:58:00 AM
From: tommysdad  Read Replies (1) of 224
 
<<He's familiar with the drug>>
OK, I'll bite. I've looked at BIOHF off and on for the past two years, and even called the company a few times. My info may be out of date, but please someone correct me if any the following is no longer true:

1) There are no clinical trials on-going or even planned in the U.S. or Europe for DIAB II.
2) There is no worldwide patent filing yet published that covers DIAB II.
3) There is no U.S. patent issued covering DIAB II.
4) The mechanism of action of DIAB II has not been disclosed in any scientific publication.
5) Sales in China have not been strong to date.
6) The structure of the chemical entity that is "DIAB II" has not been disclosed. Is it even patentable as a composition of matter?

Given these unknowns, it seems questionable that a retired surgeon could be "familiar with the drug". Are any of the above six statements no longer true (I could have missed something in the past six months)? On what factual evidence does anyone believe this is a breakout year? If DIAB II does exist (I am not saying it does not), how much do you really think they can sell in Argentina and China?

This company plays it very close to the vest. As George Carlin would say: "Could be meat, could be cake."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext